AR020403A1 - Formulacion de acidos nucleicos y acemanano - Google Patents
Formulacion de acidos nucleicos y acemananoInfo
- Publication number
- AR020403A1 AR020403A1 ARP990104496A ARP990104496A AR020403A1 AR 020403 A1 AR020403 A1 AR 020403A1 AR P990104496 A ARP990104496 A AR P990104496A AR P990104496 A ARP990104496 A AR P990104496A AR 020403 A1 AR020403 A1 AR 020403A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- formulation
- vaccine
- acemanano
- nucleic acids
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion está relacionada con la rama de la medicina, particularmente con el uso de nuevas formulaciones de adyuvantes con antigenos vacunales. El objetivo técnico que se persigue con la invencion propuesta es, precisamente, el desarrollo de formulaciones capaces de potenciar la respuesta inmune delorganismo a vacunas de ácidos nucleicos. Para lograr este objetivo se desarrollo una formulacion que contiene como componentes fundamentales al ácidonucleico vacunal y al acemmanano en proporciones adecuadas, ademas de estabilizadores y preservantes. Las formulaciones de esta invencion son aplicables enla industria farmacéutica como formulaciones vacunales para uso humano como veterinario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1998126A CU22740A1 (es) | 1998-09-07 | 1998-09-07 | Formulación de ácidos nucleicos y acemanano |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020403A1 true AR020403A1 (es) | 2002-05-08 |
Family
ID=5459419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104496A AR020403A1 (es) | 1998-09-07 | 1999-09-07 | Formulacion de acidos nucleicos y acemanano |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6358933B1 (es) |
| EP (1) | EP1029549B1 (es) |
| CN (1) | CN1287493A (es) |
| AR (1) | AR020403A1 (es) |
| AT (1) | ATE289518T1 (es) |
| BR (1) | BR9906761A (es) |
| CA (1) | CA2308444A1 (es) |
| CU (1) | CU22740A1 (es) |
| DE (1) | DE69923829D1 (es) |
| WO (1) | WO2000013704A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
| US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
| ES2294864T3 (es) * | 1999-11-03 | 2008-04-01 | Powderject Vaccines, Inc. | Vacunas geneticas potenciadas con adyuvantes. |
| US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
| US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| AU2003259109A1 (en) * | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Mesothelin vaccines and model systems |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
| IL104382A0 (en) * | 1992-01-17 | 1993-05-13 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant |
-
1998
- 1998-09-07 CU CU1998126A patent/CU22740A1/es unknown
-
1999
- 1999-09-03 WO PCT/CU1999/000004 patent/WO2000013704A1/es active IP Right Grant
- 1999-09-03 EP EP99942707A patent/EP1029549B1/en not_active Expired - Lifetime
- 1999-09-03 CN CN99801915A patent/CN1287493A/zh active Pending
- 1999-09-03 US US09/530,925 patent/US6358933B1/en not_active Expired - Fee Related
- 1999-09-03 DE DE69923829T patent/DE69923829D1/de not_active Expired - Lifetime
- 1999-09-03 AT AT99942707T patent/ATE289518T1/de not_active IP Right Cessation
- 1999-09-03 BR BR9906761-7A patent/BR9906761A/pt not_active IP Right Cessation
- 1999-09-03 CA CA002308444A patent/CA2308444A1/en not_active Abandoned
- 1999-09-07 AR ARP990104496A patent/AR020403A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69923829D1 (de) | 2005-03-31 |
| ATE289518T1 (de) | 2005-03-15 |
| WO2000013704A1 (es) | 2000-03-16 |
| EP1029549A1 (en) | 2000-08-23 |
| US6358933B1 (en) | 2002-03-19 |
| BR9906761A (pt) | 2000-10-03 |
| CU22740A1 (es) | 2002-02-28 |
| CA2308444A1 (en) | 2000-03-16 |
| CN1287493A (zh) | 2001-03-14 |
| EP1029549B1 (en) | 2005-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| CY1108875T1 (el) | Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| ES2133477T3 (es) | Forma de dosificacion que comprende un antigeno y una forma salina de un derivado de acido organico de un esterol. | |
| AR032597A1 (es) | Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli | |
| ES2069435T3 (es) | Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos. | |
| ES2164251T3 (es) | Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre. | |
| BR0016022A (pt) | Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide | |
| BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
| PT815235E (pt) | Vacinas para peste | |
| BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
| AR072378A1 (es) | Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos. | |
| ES2116986T3 (es) | Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello. | |
| BR0011116A (pt) | Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas | |
| BR0209041A (pt) | Emplastro de imunização de disposição de microprojeção e método | |
| PE20011217A1 (es) | Composicion farmaceutica para modulacion inmunologica y preparacion de vacunas | |
| AR020403A1 (es) | Formulacion de acidos nucleicos y acemanano | |
| CU22871A1 (es) | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| AR039982A1 (es) | Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas | |
| BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
| BR0208980A (pt) | Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses | |
| ES2036661T3 (es) | Un metodo para preparar una preparacion farmaceutica de pie de atleta. | |
| BR9808832A (pt) | Formulações de vacina para uso nasofarìngeo, uso mucosal e uso sistêmico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |